PD-L1 and LC3B expression in Glioblastoma; is it a promising prognostic and therapeutic targets?
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background GBM, the most common primary malignant brain tumor in adults, has a poor prognosis. Immunotherapy targeting the PD-1/PD-L1 axis has shown limited success in GBM. Resistance to therapies involves pathways like autophagy. Detecting LC3B expression provides a simple technique for monitoring autophagy. Our goal was to understand the interplay between PD-L1 and LC3B in GBM prognosis and treatment strategies. Methods The study analyzed 61 GBM specimens to assess the immunohistochemical expression of PD-L1 and LC3B with investigating their correlation with various clinicopathological parameters with assessing the impact of PD-L1 and LC3B expression on patients’ survival and the relation between both markers. Results Both PD-L1 and LC3B were significantly associated with clinicopathological parameters, including Karnofsky performance score (KPS)(p = 0.028 and 0.004 respectively), surgical resection extent (p = 0.023 and 0.002), treatment response(p = 0.015, p ≤ 0.001), patient outcome(p ≤ 0.001), and recurrence (p ≤ 0.001). There was a statistically significant inverse correlation between overall survival (OS) and both PD-L1 and LC3B expression. Additionally, there was a statistically significant inverse correlation between progression-free survival (PFS) and LC3B expression. PD-L1 expression and adjuvant chemotherapy were identified as independent prognostic factors for overall survival in GBM cases. A statistically significant positive relation existed between PD-L1 and LC3B (p ≤ 0.001). Conclusion Results of this study suggest that the robust expression of PD-L1 in glioblastoma is associated with poor prognosis. Additionally, high expression of LC3B in GBM suggests increased autophagic activity which associated with unfavourable outcome. Combining immunotherapy with autophagy modulators could be a promising approach for improving GBM treatment.